Bioinvent International Ab · OMXSTO:BINV

Bioinvent International Ab — Investor Presentation (October 2026)

46 slides from Bioinvent International Ab's investor presentation, October 2026

  1. Slide 1: The Next-Generation Immunotherapy of Cancer

    THE NEXT-GENERATION IMMUNOTHERAPY OF CANCER October 2026

  2. Slide 2: Disclaimer

    Disclaimer This presentation is not a prospectus or other offer document and has not been approved by any regulatory authority in any jurisdiction. The information contained in this presentation has been prepared solely for information purposes. It is not intended for potential investors and does no

  3. Slide 3: BioInvent is Developing the New Standard of Care for Recurring Ovarian Cancer

    BioInvent is Developing the New Standard of Care for Recurring Ovarian Cancer - $1.7 billion in estimated peak sales 3

  4. Slide 4: Swedish clinical-stage biotech developing first-in-class immune-modulating antibodies

    We are a Swedish clinical-stage biotech developing first-in-class immune- modulating antibodies to treat cancer o Cancer immunotherapies with novel MoAs and excellent safety profiles 4 Ongoing Clinical o Phase 2 trials ongoing with early evidence of efficacy Programs o History of successful partners

  5. Slide 5: Function F.I.R.S.T Enables Discovery of New Oncology Targets and Antibodies

    Function F.I.R.S.T Enables Discovery of New Oncology Targets and Antibodies 5

  6. Slide 6: First-in-class Clinical Assets Advancing Across Multiple Indications

    BioInvent has First-in-class Clinical Assets Advancing Across Multiple Indications Compound/Indication Phase 1 Phase 2a Phase 2b Milestone TNFR2 Ovarian cancer Ongoing ➔ Further Phase 2a data at ESMO Oct 2026 Pembrolizumab1 Ovarian cancer First Phase 2a data Planned ➔ Pembrolizumab1 + Paclitaxel exp

  7. Slide 7: Anti-TNFR2

    ANTI-TNFR2 BI-1808 in Ovarian Cancer BI-1808 in T-cell Lymphoma 7

  8. Slide 8: BI-1808's Differentiated Mechanism of Action

    BI-1808’s Differentiated Mechanism of Action Depletes Tregs and activates macrophages to induce CD8+ T cell antitumor immunity Mårtensson et al, BioRxiv + anti-PD-1 Mårtensson, et al (Cancer Research https://doi.org/10.1158/0008-5472.CAN-26-0274) 8

  9. Slide 9: BI-1808 Clinical Trial Design Phase 1/2A

    TNFR2 BI-1808 BI-1808 Clinical Trial Design Phase 1/2A (KEYNOTE-D20) Phase 1 Phase 2a All Cancer Types Tissue-specific Cohorts Dose Escalation Signal Seeking Randomization mTPI2 design n=12 subjects per cohort n=10/20 subjects per cohort between 1000 mg and 250/500 mg BI-1808 1000 mg 6 additional 1.

  10. Slide 10: BI-1808: Strong Single Agent Activity in Solid Tumors

    TNFR2 BI-1808 BI-1808: Strong Single Agent Activity in Solid Tumors Link to poster • Heavily pre-treated, end-of the-line ASCO 2024 Poster Presentation patients • 1 complete response (CR) in ovarian cancer • 1 partial response (PR) in GIST that continued through the full study treatment. Multiple bi

  11. Slide 11: Single Agent Case Study: Complete Response in Ovarian Cancer

    TNFR2 BI-1808 BI-1808 Single Agent Case Study: Complete Response in Ovarian Cancer Baseline 2 months 63-year-old patient with ovarian cancer, Stage IIIA at diagnosis, entered the study with PD. Four previous lines of treatment: • Paclitaxel/carboplatin • Carboplatin/doxorubicin • Olaparib • Bevacizu

  12. Slide 12: Single Agent Case Study: Robust PR in a Patient with GIST

    TNFR2 BI-1808 BI-1808 Single Agent Case Study: Robust PR in a Patient with GIST* Baseline Follow-up 13 months 55-year-old male patient with GIST, who presented with clinical PD for more than six months with multiple metastatic lesions. 12 previous lines of therapy. Pre-dose Week 5 Blue = DAPI Blue =

  13. Slide 13: BI-1808 in Ovarian Cancer

    BI-1808 in Ovarian Cancer ‘SBiolnvent | 13

  14. Slide 14: BI-1808 + Pembrolizumab Achieves 24% ORR in Recurrent Ovarian Cancer

    TNFR2 BI-1808 BI-1808 + Pembrolizumab Achieves 24% ORR in Heavily Pretreated Recurrent Ovarian Cancer Patients No Chemotherapy Regimen PATIENT PROFILE TREATMENT HISTORY TREATMENT RESPONSE 26 Enrolled patients, 25 evaluable 5 median prior lines 24% overall response rate (ORR) Tumor Subtypes Prior Tre

  15. Slide 15: BI-1808 + Pembrolizumab: Promising Efficacy In Ovarian Cancer

    TNFR2 BI-1808 BI-1808 + Pembrolizumab: Promising Efficacy In Ovarian Cancer Data presented at ASCO 2026 Phase / Design Population N Dosing Sites Key Endpoints Data Cut-off Ph2a single arm BI-1808 1000 mg Q3W Safety OC (all subtypes) 25 of 40 8 (OC) in EU & UK 2026-04-20 (doublet) Pembro 200 mg Q3W O

  16. Slide 16: Late Responses Signal Deeper, More Durable Activity

    TNFR2 Late Responses Signal Deeper, More Durable Activity: BI-1808 A Feature of BI-1808's Mechanism ccOC (clear cell) — responses observed HGSA (high-grade serous) — responses observed Activity in both subtypes: high-grade serous (HGSA) and clear cell (ccOC) Late responses: a hidden positive feature

  17. Slide 17: Treatment Paradigm Shaped by Platinum Sensitivity and Biomarker Status

    TNFR2 BI-1808 The Treatment Paradigm is Shaped by Platinum Sensitivity and Biomarker Status; With Few Recent Approvals in PROC* Platinum Sensitive (PSOC) ≥6 months Platinum resistant (PROC) <6 months 1st Relapse 1L 2L 3L 4L+ mPFS ~5.5-8m mPFS ~4.4m Surgery Platinum doublet +/- Beva Paclitaxel, PLD,

  18. Slide 18: The Treatment Paradigm is Changing with Few Recent Approvals in PROC

    The Treatment Paradigm is Changing with Few Recent Approvals in PROC Isabelle Ray-Coquard & Kathleen N. Moore 18

  19. Slide 19: ADCs are not a competitive threat

    ADCs are not a competitive threat — and they may complement BI-1808 Four structural limitations of the ADC class Significant toxicity Biomarker-restricted Near-universal Only two payload resistance classes Boxed warnings across the class: MIRV requires FRα-high — only Resistance develops in almost T

  20. Slide 20: BI-1808 as the Next Standard of Care in Ovarian Cancer

    BioInvent’s BI-1808 as the Next Standard of Care in Ovarian Cancer Estimated peak sales of BI-1808 in PROC of ~$1.7 billion (base-case) for current target product profile (TPP) CURRENT NEXT FORECAST • Standard of care (SoC) • BI-1808 on top of Region Peak Sales Peak Year in ovarian cancer the curren

  21. Slide 21: Positioning BI-1808 in Recurring Ovarian Cancer

    TNFR2 BI-1808 Positioning BI-1808 in Recurring Ovarian Cancer • First-in-class BI-1808 depletes immunosuppressive Tregs and reprograms macrophages to expand and activate CD8+ effector T cells, converting the tumor microenvironment from “cold" to “hot." • Pembrolizumab + paclitaxel achieved 53% ORR,

  22. Slide 22: BI-1808 in CTCL

    BI-1808 in CTCL ‘SBiolnvent | 22

  23. Slide 23: Impressive Responses in Heavily Pre-treated PTCL or CTCL Patients

    Impressive Responses Were Observed in Heavily Pre-treated Patients with PTCL or CTCL Treated with BI-1808 Monotherapy Case Studies PTCL Patient CTCL Patient (stage IV, 6 prior lines of treatment) (stage IIb MF, 5 prior lines of treatment) Baseline Week 9 Baseline Week 21 23

  24. Slide 24: BI-1808 Clinical Phase 1/2a Study Overview

    TNFR2 BI-1808 BI-1808 Clinical Phase 1/2a Study Overview Orphan Drug Designation • Safety and preliminary efficacy currently investigated in CTCL patients (sub-cohort of the ongoing Phase for TCL 2a clinical trial) Fast Track Designation for CTCL • 20 patients enrolled for BI-1808 1000 mg as single

  25. Slide 25: BI-1808 Shows Promising Efficacy in CTCL (and PTCL)

    TNFR2 BI-1808 BI-1808 Shows Promising Efficacy in CTCL (and PTCL) EHA 2026 poster Phase 2a monotherapy & combination data Single Agent (2A CTCL) — mSWAT + Pembrolizumab (2B CTCL) — mSWAT PTCL 40% 93% 1 CR 50% 75% 4 PR ORR DCR SS ongoing 2+ yrs ORR DCR 5 PRs + 1 CR 15 evaluable pts 4 PRs 8 evaluable

  26. Slide 26: BI-1808 Differentiated in Mycosis Fungoides

    BI-1808 is Differentiated Where it Matters Most: Mycosis Fungoides MF represent the majority of CTCL patients (~70%), and where incumbents are weakest BI-1808 • Higher efficacy in MF than all other treatments except for brentuximab (30% of patients, black box warning) • No biomarker restriction • Be

  27. Slide 27: BI-1808 Potential Path to Approval – US

    TNFR2 BI-1808 BI-1808 Potential Path to Approval – US Breakthrough Designation Potential Timelines for Ovarian Cancer* Agreed Pivotal Design Fast Track Designation ✓ EOP Meeting ✓ Phase 2, Part A Randomized study in combo with monotherapy (n=20) Phase 2, Part B pembro and paclitaxel vs SoC Combo wit

  28. Slide 28: A Pragmatic Development Strategy With Billion-Dollar Potential

    A Pragmatic Development Strategy With Billion-Dollar Potential $ multi billion • Pursue Fast to market indication in CTCL (plan for BTD and accelerated approval) Other “cold” tumors • Develop triplet regimen with BI-1808 +pembrolizumab+paclitaxel in PROC Ovarian Cancer Earlier lines • Future develop

  29. Slide 29: Anti-FcγRIIB

    ANTI-FcγRIIB BI-1206 in Solid Tumors BI-1206 in Non-Hodgkin’s Lymphoma (NHL) 29

  30. Slide 30: BI-1206 in Solid Tumors

    BI-1206 in Solid Tumors: Non-Small Cell Lung Cancer Uveal Melanoma 30

  31. Slide 31: BI-1206 with Pembrolizumab: Responses in Uveal Melanoma

    FcyRIIB BI-1206 Co-administration of BI-1206 with Pembrolizumab - Promising Responses in Uveal Melanoma Who Previously Failed anti-PD-1 Baseline End of treatment 2 years Case study: PR 69 YO female with uveal melanoma. No response to prior immunotherapy or chemotherapy. Multiples lines of ICIs and C

  32. Slide 32: BI-1206 with Pembrolizumab: Responses in Melanoma

    FcyRIIB Co-administration of BI-1206 with Pembrolizumab Promising Responses BI-1206 Observed in Melanoma, who Previously Failed Anti-PD-1 Therapy Baseline Scan at 16 months Case study: CR 77 YO male melanoma patient, stage IV. Deep Partial Response at first scan at 2 months, evolving to CR at 10 mon

  33. Slide 33: Phase 2a Ongoing: BI-1206 + Keytruda in Treatment-Naïve Patients

    FcyRIIB BI-1206 Phase 2a study Ongoing: BI-1206 + KEYTRUDA in Treatment-Naïve Patients • To evaluate safety and efficacy of BI-1206 in combination with pembrolizumab • Advanced or metastatic NSCLC and uveal melanoma • Patients will be enrolled at sites in Georgia, Germany, Poland, Romania, Spain, Sw

  34. Slide 34: Competitive Landscape in PD-L1 High NSCLC

    Competitive Landscape in PD-L1 High NSCLC BI-1206 + pembro opportunity Grey bubble: Non-approved Colored bubble: Approved Bubble size: No. of pts in reference trial 34

  35. Slide 35: Positioning of BI-1206 in Non-Small Cell Lung Cancer

    FcyRIIB BI-1206 Positioning of BI-1206 in Non-Small Cell Lung Cancer • BI-1206 blocks FcγRIIB (CD32b), a receptor on myeloid cells that actively removes anti-PD-1 antibodies off T-cells, internalizing and degrading them. By blocking FcγRIIB, BI-1206 prevents the removal of pembrolizumab from the T-c

  36. Slide 36: BI-1206 in NHL

    BI-1206 in NHL ‘YBiolnvent | 36

  37. Slide 37: BI-1206 Can Compete in a Highly Competitive FL Market

    FcyRIIB BI-1206 Paired with Entrenched Rituximab, BI-1206 can Compete in a Highly Competitive FL Market Now Follicular Lymphoma (FL) Market Shifts Other MOA • Increasing bispecific options Bispecifics • Expansion of other MOAs (BTKi, CAR-T) Rituximab- based • Switch to rituximab biosimilars regimens

  38. Slide 38: BI-1206 Clinical Study Overview

    FcyRIIB BI-1206 BI-1206 Clinical Study Overview • Phase 1: BI-1206 enhances the activity of rituximab (next slide) • Phase 2a: Adding acalabrutinib to the combination results in impressive efficacy (and Safety!) Phase 1 Phase 2a BI-1206 + rituximab (Doublet) BI-1206 + rituximab + acalabrutinib (Trip

  39. Slide 39: Triplet Combination Results in High Response Rates Across NHL Subtypes

    FcyRIIB BI-1206 Triplet Combination Results in High Response Rates Across NHL Subtype No CRS · No ICANS 83% ORR (n=23) 48% CRR 100% DCR 81% ORR in FL (n=16) 44% CRR in FL No increased infection rate • ORR of 83%, CRR of 48% and DCR of 100% (n=23) • Best Response in 23 evaluable patients: – 11 comple

  40. Slide 40: BI-1206 + Rituximab + Calquence Triplet: Best Response

    FcyRIIB BI-1206 BI-1206 + Rituximab + Calquence* Triplet: Best Response (FL, MZL, MCL) PR * Acalabrutinib, supplied by AstraZeneca. Data cut-off 2026-05-06 40

  41. Slide 41: BI-1206 in NHL: Potential Timelines

    BI-1206 in NHL: Combination with Rituximab + Acalabrutinib - Potential Timelines *Type B FDA meeting Type B FDA meeting *Agreed Pivotal Phase 2 BLA submission design Breakthrough Therapy Designation Approval Phase 2a Signal Seeking Phase 2a follow up Pivotal Study - Phase 2*# (Submission in Q1) Conf

  42. Slide 42: BI-1206 Positioning in Follicular Lymphoma

    FcyRIIB BI-1206 BI-1206 Positioning in Follicular Lymphoma • In FL, repeated exposure to Rituximab leads to resistance via FcγRIIB-mediated internalization; BI-1206 blocks this escape route, potentially "resensitizing" the tumor to CD20 therapy even in heavily pre-treated patients. • While BTK inhib

  43. Slide 43: Key Expected Milestones 2026-2027

    Key Expected Milestones 2026-2027 2026 2027 Ovarian cancer TNFR2 ✓ Additional Phase First Phase 2a data Additional Phase 2a 2a data with triplet + Keytruda Keytruda data with Keytruda +Paclitaxel CTCL ✓ First Phase 2a data with Complete Phase 2a Keytruda + additional data dose optimization, Potentia

  44. Slide 44: www.bioinvent.com

    * Biolnvent bringing antibodies to life

  45. Slide 45: Appendix

    Appendix 45

  46. Slide 46: BioInvent Management Team

    46 │ BioInvent Management Team Martin Welschof, Ph.D. Stefan Ericsson Andres McAllister, M.D., Ph.D. Björn Frendéus, Ph.D. Chief Executive Officer Chief Financial Officer Chief Medical Officer Chief Scientific Officer 8 28 9 25 Ashley Robinson Ingunn Munch Lindvig, Ph.D. Kristoffer Rudenholm Hansson

BioInvent International — Investor Presentation (October 2026) on 6ix